Table 1.
UACR (mg/gCr) | P across groups | |||
---|---|---|---|---|
<30 | 30‐<300 | ≥300 | ||
N | 661 | 278 | 49 | |
Age (y) | 57.7 (10.2) | 59.7 (10.5) | 60.1 (9.9) | .01 |
Sex, n male/female | 435 / 226 | 193 / 85 | 33 / 16 | n.s. |
TOFO 10 mg / 20 mg / 40 mg | 40 / 195 / 426 | 15 / 82 / 181 | 2 / 16 / 31 | n.s. |
Body weight (kg) | 67.7 (13.7) | 69.3 (14.0) | 72.6 (15.8) | .03 |
BMI (kg/m2) | 25.3 (4.2) | 26.0 (4.3) | 26.5 (4.2) | .01 |
HbA1c (%) | 8.0 (0.9) | 8.2 (0.9) | 8.3 (1.0) | .001 |
HbA1c (mmol/mol) | 64.2 (9.5) | 66.5 (10.2) | 67.7 (10.9) | |
Fasting plasma glucose (mg/dL) | 159.5 (35.4) | 166.9 (35.0) | 171.2 (47.0) | .003 |
Fasting plasma glucose (mmol/L) | 8.9 (2.0) | 9.3 (1.9) | 9.5 (2.6) | |
Systolic BP (mm Hg) | 128.4 (13.9) | 133.0 (13.8) | 136.9 (13.3) | <.0001 |
Diastolic BP (mm Hg) | 77.1 (9.8) | 78.7 (10.9) | 78.7 (12.6) | n.s. |
Concomitant antihyperglycemic drugs (%) | 60.1 | 62.9 | 61.2 | n.s. |
alpha‐GI / Biguanide / DPP‐4I / Glinide / Sulfonylurea / Thiazolidine | 64 / 62 / 68 / 16 / 113 / 74 | 26 / 36 / 35 / 4 / 50 / 24 | 6 / 1 / 5 / 2 / 15 / 1 | – |
Concomitant antihypertensive drugs (%) | 39.6 | 55.4 | 67.4 | <.0001 |
ARB / ACEI / CCB / beta‐blockers / diuretics | 195 / 10 / 139 / 19 / 51 | 118 / 9 / 105 / 13 / 17 | 23 / 3 / 29 / 2 / 5 | – |
Duration of diabetes mellitus (y) | 6.8 (5.8) | 7.0 (6.0) | 7.5 (5.8) | n.s. |
Creatinine (mg/dL) | 0.70 (0.15) | 0.73 (0.21) | 0.87 (0.29) | <.0001 |
eGFRMDRD (mL/min/1.73 m2) | 88.8 (18.7) | 87.6 (23.6) | 74.5 (25.0) | <.0001 |
eGFRcys (mL/min/1.73 m2) | 110.5 (22.5) | 104.4 (26.1) | 86.5 (27.3) | <.0001 |
UACR (mg/gCr) | 11.2 | 68.3 | 775.4 | <.0001 |
UACR (mg/mmolCr) | 1.3 | 7.7 | 87.7 | |
Urinary NAG (U/gCr) | 6.4 | 8.8 | 14.5 | <.0001 |
Urinary NAG (U/mmolCr) | 0.7 | 1.0 | 1.6 | |
Urinary beta‐2MG (mg/gCr) | 115.2 | 161.3 | 347.4 | <.0001 |
Urinary beta‐2MG (μg/mmolCr) | 13.0 | 18.2 | 39.3 |
ACEI, ACE inhibitor; alpha‐GI, alpha‐glucosidase inhibitor; beta‐2MG, β2 microglobulin; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; DPP‐4I, dipeptidyl peptidase‐4 inhibitor; eGFRMDRD, estimated glomerular filtration rate; eGFRcys, estimated glomerular filtration rate calculated from cystatin C; HbA1c, glycated haemoglobin; NAG, N‐acetyl‐β‐d‐glucosaminidase; TOFO, tofogliflozin; UACR, urine albumin‐to‐creatinine ratio.
Mean (standard deviation).
Median for UACR and tubular indices.
ANOVA across groups for continuous variables. Kruskal‐Wallis test across groups for urinary indices. Fisher's exact test across groups for categorical variables.